Coley Pharmaceutical obtained a $3 million milestone payment from GlaxoSmithKline (GSK). The payment is associated with GSK’s initiation of its Phase III trial in non-small-cell lung cancer (NSCLC) investigating an immunotherapeutic cancer vaccine containing Coley’s VaxImmune™ vaccine adjuvant.
In June 2007, GSK began a Phase III trial in lung cancer to evaluate MAGE-A3 antigen-specific cancer immunotherapeutic (MAGE-A3 ASCI) in patients with early-stage, completely resected NSCLC. VaxImmune is one of the components of MAGE-A3 ASCI, intended to increase an antitumor immune response.
VaxImmune is Coley’s TLR9 agonist designed to induce both an enhanced antibody response and a potent killer T-cell immune response when used in conjunction with vaccines to achieve and sustain a clinical response without compromising safety. Coley has granted GSK worldwide licenses for the use of VaxImmune in the development of vaccines for certain cancers and infectious diseases.